Zevra Therapeutics (ZVRA) EBITDA (2014 - 2026)
Zevra Therapeutics (ZVRA) reported EBITDA of $52.1 million for Q1 2026, up 1072.51% on a YoY basis from $4.4 million in Q1 2025, and up 459.81% quarter-over-quarter from $9.3 million in Q4 2025.
Zevra Therapeutics (ZVRA) EBITDA (2014 - 2026) Analysis & Trends
Zevra Therapeutics has reported EBITDA for 13 years, with the latest figure at $52.1 million in Q1 2026.
- For the quarter ending Q1 2026, EBITDA rose 1072.51% year-over-year to $52.1 million; the trailing twelve-month figure through Mar 2026 stood at -$5.4 million (up 92.44% YoY), and the FY2025 full-year result was -$62.7 million, up 27.72% from the prior year.
- EBITDA for Q1 2026 stood at $52.1 million, up from $9.3 million in the prior quarter.
- The five-year high for EBITDA was $52.1 million in Q1 2026, with the low at -$71.0 million in Q2 2025.
- Historically, EBITDA has averaged -$9.3 million across 5 years, with a median of -$9.3 million in 2022.
- Annual changes were most pronounced in 2023 — EBITDA sank 12925.0% — and 2026, when it jumped 1072.51%.
- Zevra Therapeutics' EBITDA stood at -$9.3 million in 2022, then tumbled by 62.75% to -$15.2 million in 2023, then slipped by 1.71% to -$15.4 million in 2024, then soared by 160.42% to $9.3 million in 2025, then soared by 459.81% to $52.1 million in 2026.
- The last three EBITDA figures came in at $52.1 million (Q1 2026), $9.3 million (Q4 2025), and $4.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | -26.92 Mn |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | -13.63 Mn |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | -19.70 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | -14.44 Mn |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | -3.82 Mn |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | -752,618.00 |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 1.14 Bn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | -65.83 Mn |
| 10 | Zevra Therapeutics | 704.96 Mn | 504.34 Mn | 34.30 Mn | 52.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 52.15 Mn |
| Dec 31, 2025 | 9.32 Mn |
| Sep 30, 2025 | 4.14 Mn |
| Jun 30, 2025 | -71.04 Mn |
| Mar 31, 2025 | -5.36 Mn |
| Dec 31, 2024 | -15.42 Mn |
| Sep 30, 2024 | -27.31 Mn |
| Jun 30, 2024 | -23.80 Mn |
| Mar 31, 2024 | -20.49 Mn |
| Dec 31, 2023 | -15.16 Mn |
| Sep 30, 2023 | -15.36 Mn |
| Jun 30, 2023 | -6.25 Mn |
| Mar 31, 2023 | -12.83 Mn |
| Dec 31, 2022 | -9.31 Mn |
| Sep 30, 2022 | -123,000.00 |
| Jun 30, 2022 | -48,000.00 |
| Mar 31, 2022 | -1.86 Mn |
| Dec 31, 2021 | -2.84 Mn |
| Sep 30, 2021 | -2.22 Mn |
| Jun 30, 2021 | 5.83 Mn |